Holen Sie sich die Stockscreener-App
30.10
2.59%
-0.83
Schlusskurs vom Vortag:
$30.93
Offen:
$30.38
24-Stunden-Volumen:
6,765
Relative Volume:
0.13
Marktkapitalisierung:
$372.48M
Einnahmen:
$9.71M
Nettoeinkommen (Verlust:
$-29.96M
KGV:
-8.6494
EPS:
-3.48
Netto-Cashflow:
$-14.79M
1W Leistung:
-6.22%
1M Leistung:
-9.74%
6M Leistung:
+20.52%
1J Leistung:
+0.00%
1-Tages-Spanne:
$29.77
$30.86
1-Wochen-Bereich:
$29.07
$33.50
52-Wochen-Spanne:
$18.35
$39.92
Xoma Royalty Corp Stock (XOMA) Company Profile
Firmenname
Xoma Royalty Corp
Sektor
Branche
Telefon
510-204-7239
Adresse
2200 POWELL STREET, EMERYVILLE, CA
Vergleichen Sie XOMA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XOMA
Xoma Royalty Corp
|
30.08 | 385.49M | 9.71M | -29.96M | -14.79M | -3.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.70 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
729.43 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
462.33 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
904.45 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.81 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xoma Royalty Corp Stock (XOMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-17 | Eingeleitet | The Benchmark Company | Buy |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2021-09-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-06-29 | Eingeleitet | Aegis Capital | Buy |
| 2021-01-19 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-18 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-17 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-05 | Hochstufung | Wedbush | Neutral → Outperform |
| 2017-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-11-14 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-11 | Bestätigt | Wedbush | Outperform |
| 2015-07-23 | Herabstufung | Jefferies | Buy → Hold |
| 2015-07-22 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2015-07-22 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-10-10 | Fortgesetzt | ROTH Capital | Buy |
| 2014-04-29 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-03-11 | Herabstufung | MLV & Co | Buy → Hold |
| 2014-03-05 | Bestätigt | Ladenburg Thalmann | Buy |
| 2013-10-31 | Bestätigt | MLV & Co | Buy |
| 2013-05-09 | Bestätigt | Ladenburg Thalmann | Buy |
| 2012-05-14 | Eingeleitet | Cowen & Co | Outperform |
| 2011-03-31 | Bestätigt | MLV Capital | Buy |
| 2011-03-23 | Bestätigt | RBC Capital Mkts | Outperform |
| 2011-01-06 | Bestätigt | Ladenburg Thalmann | Buy |
| 2011-01-04 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Xoma Royalty Corp Aktie (XOMA) Neueste Nachrichten
XOMA Royalty completes acquisition of Mural Oncology for $2.035 per share - Investing.com Canada
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc - Yahoo Finance
XOMA Royalty completes acquisition of Mural Oncology - Investing.com
Mural Oncology plc Announces Effective Date of Scheme Arrangement for Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology (Nasdaq: MURA) scheme with XOMA unit effective as Nasdaq listing ends - Stock Titan
Why XOMA Royalty Corporation (X0M1) stock could be top winnerJuly 2025 Outlook & Weekly High Return Stock Opportunities - Newser
Will XOMA Royalty Corporation (X0M1) stock test record highs in 20252025 Price Action Summary & Weekly High Return Forecasts - Newser
Why XOMA Royalty Corporation (X0M1) stock appeals to dividend investorsEarnings Recap Report & Capital Efficient Trade Techniques - Newser
What earnings margins imply for XOMA Royalty Corporation(X0M) stockIPO Watch & Risk Managed Investment Strategies - Newser
Irish court approves XOMA Royalty’s acquisition of Mural Oncology By Investing.com - Investing.com India
Mural Oncology Announces Sanction of the Scheme by the High Court - The Manila Times
Mural Oncology plc Announces Court Approval of Scheme for Acquisition by XOMA Royalty Corporation's Subsidiary - Quiver Quantitative
Mural Oncology Announces Sanction of the Scheme by the High Court - Benzinga
Is XOMA Royalty Corporation (X0M1) stock a defensive play amid uncertaintyMarket Activity Summary & Weekly Watchlist for Consistent Profits - Newser
How robust is XOMA Royalty Corporation(X0M) stock financial position - Newser
XOMA Royalty (NASDAQ:XOMA) Stock Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Mural Oncology Shareholders To Receive $2.035 Cash Per Share In XOMA Royalty Acquisition - Nasdaq
XOMA Royalty to acquire Mural Oncology for $2.035 per share By Investing.com - Investing.com Nigeria
XOMA Royalty to acquire Mural Oncology for $2.035 per share - Investing.com India
Mural Oncology announces final cash consideration payable on acquisition close - TipRanks
Mural Oncology plc Announces Final Determination of Additional Price Per Share in Acquisition by XOMA Royalty Corporation - Quiver Quantitative
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty - The Manila Times
Mural Oncology (Nasdaq: MURA) to Be Acquired by XOMA Royalty for $2.035 Cash - Stock Titan
XOMA (NASDAQ:XOMAP) Trading 0.2% Higher – Should You Buy? - Defense World
Xoma completes $24.9M acquisition of cash-strapped Lava Therapeutics - The Business Journals
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - ADVFN
Xoma announces closing of transactions to acquire Lava Therapeutics - TipRanks
XOMA Royalty completes acquisition of LAVA Therapeutics - Investing.com
[8-K] XOMA Royalty Corp Reports Material Event - Stock Titan
XOMA Royalty completes acquisition of LAVA Therapeutics By Investing.com - Investing.com UK
XOMA Royalty Corporation Completes Acquisition of LAVA Therapeutics N.V. - Quiver Quantitative
XOMA Royalty (Nasdaq: XOMA) completes LAVA deal; investors get $1.04 plus CVR - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
How XOMA Royalty Corporation (X0M1) stock reacts to Fed tighteningJobs Report & High Accuracy Trade Alerts - newser.com
How XOMA Royalty Corporation stock performs after earningsEarnings Recap Report & Long-Term Safe Investment Ideas - newser.com
How XOMA Royalty Corporation(X0M) stock behaves under inflation pressure2025 Market Sentiment & Risk Adjusted Buy and Sell Alerts - newser.com
Is XOMA Royalty Corporation stock a safe buy before earningsRate Hike & Verified Momentum Stock Watchlist - newser.com
Is XOMA Royalty Corporation (X0M1) stock attractive for dividend growthNew Guidance & High Conviction Investment Ideas - newser.com
Can XOMA Royalty Corporation (X0M1) stock attract analyst upgrades2025 Earnings Impact & Reliable Trade Execution Plans - newser.com
Why XOMA Royalty Corporation stock remains undervaluedJuly 2025 Setups & Technical Confirmation Trade Alerts - newser.com
How XOMA Royalty Corporation stock compares to market leadersTreasury Yields & AI Enhanced Market Trend Forecasts - newser.com
XOMA Royalty's (NASDAQ:XOMA) Earnings Aren't As Good As They Appear - Yahoo Finance
How strong is XOMA Royalty Corporation stock revenue growthEarnings Performance Report & Weekly High Return Stock Opportunities - newser.com
Why millennials buy XOMA Royalty Corporation (X0M1) stock2025 Trading Volume Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Will XOMA Royalty Corporation stock keep outperforming rivals2025 Short Interest & Fast Gaining Stock Reports - newser.com
XOMAO | XOMA Royalty Corporation Depositary Stock Data, Price & News - Quiver Quantitative
XOMAO Stock Institutional Owners - Quiver Quantitative
LuxembourgXOMA Royalty Acquires LAVA Therapeutics - Mondaq
Xoma turns its attention to Repare | ApexOncoClinical Trials news and analysis - Oncology Pipeline
XOMAP | XOMA Royalty Corporation 8.625% Stock Data, Price & News - Quiver Quantitative
Q4 EPS Estimates for XOMA Royalty Cut by Leerink Partnrs - Defense World
Finanzdaten der Xoma Royalty Corp-Aktie (XOMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.29%
0.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):